Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021

EWTX Insider Trading (Edgewise Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $10,250,000.00
Insider Selling (Last 12 Months): $0.00

Edgewise Therapeutics Insider Trading History Chart

Edgewise Therapeutics Share Price & Price History

$26.05
▼ -1.25 (-4.58%)
As of 06/22/2021 01:13 PM ET
Days: 30 | 90 | 365
Revealed: A Real Solution for Depression?
Depression is the leading cause of disability worldwide. For nearly 100 million people… there's no known solution. That's right. Nearly one-third of the world's 322 million people suffering from depression have no existing treatment. But that's all about to change.
Here's how you could capitalize off this

Edgewise Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/30/2021James E FlynnMajor ShareholderBuy625,000$16.00$10,000,000.004,962,207View SEC Filing Icon  
3/30/2021Jonathan D RootDirectorBuy15,625$16.00$250,000.0015,625View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Edgewise Therapeutics (NASDAQ:EWTX)

91.84% of Edgewise Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Edgewise Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/21/2021Citadel Advisors LLC2,382,148$77.42M0.0%N/A4.836%Search for SEC Filing on Google Icon
5/19/2021Logos Global Management LP1,056,812$34.35M3.4%N/A2.146%Search for SEC Filing on Google Icon
5/19/2021Octagon Capital Advisors LP125,000$4.06M1.5%N/A0.254%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC20,185$0.66M0.0%N/A0.041%Search for SEC Filing on Google Icon
5/18/2021Baker BROS. Advisors LP500,000$16.25M0.1%N/A1.015%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC60,077$1.95M0.0%N/A0.122%Search for SEC Filing on Google Icon
5/18/2021RA Capital Management L.P.2,613,623$84.94M1.3%N/A5.306%Search for SEC Filing on Google Icon
5/18/2021Orbimed Advisors LLC13,944,680$453.20M4.2%N/A29.316%Search for SEC Filing on Google Icon
5/18/2021Cormorant Asset Management LP2,340,914$74.31M1.7%N/A4.921%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC2,382,148$77.42M0.0%N/A5.008%Search for SEC Filing on Google Icon
5/17/2021Viking Global Investors LP3,352,249$108.95M0.3%N/A7.047%Search for SEC Filing on Google Icon
5/17/2021Deerfield Management Company L.P. Series C3,933,137$127.83M2.7%N/A8.269%Search for SEC Filing on Google Icon
5/17/2021Woodline Partners LP357,429$11.62M0.3%N/A0.751%Search for SEC Filing on Google Icon
5/17/2021EcoR1 Capital LLC1,224,175$39.79M1.8%N/A2.574%Search for SEC Filing on Google Icon
5/17/2021Caas Capital Management LP30,000$0.98M0.0%N/A0.063%Search for SEC Filing on Google Icon
5/17/2021Janus Henderson Group PLC2,140,908$65.15M0.0%N/A4.501%Search for SEC Filing on Google Icon
5/17/2021Sphera Funds Management LTD.100,000$3.25M0.2%N/A0.210%Search for SEC Filing on Google Icon
5/17/2021Novo Holdings A S5,587,207$181.58M7.5%N/A11.746%Search for SEC Filing on Google Icon
5/17/2021Goldman Sachs Group Inc.65,263$2.12M0.0%N/A0.137%Search for SEC Filing on Google Icon
5/14/2021Credit Suisse AG84,052$2.73M0.0%N/A0.177%Search for SEC Filing on Google Icon
5/13/2021Federated Hermes Inc.616,724$20.04M0.0%N/A1.297%Search for SEC Filing on Google Icon
5/12/2021New Leaf Venture Partners L.L.C.1,553,661$50.49M11.9%N/A3.266%Search for SEC Filing on Google Icon
5/11/2021Landscape Capital Management L.L.C.8,923$0.29M0.0%N/A0.019%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Edgewise Therapeutics logo
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Read More on Edgewise Therapeutics

Today's Range

Now: $26.05
$26.05
$27.20

50 Day Range

MA: $27.51
$25.19
$29.35

52 Week Range

Now: $26.05
$21.07
$40.49

Volume

664 shs

Average Volume

189,901 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Edgewise Therapeutics?

Edgewise Therapeutics' top insider investors include:
  1. James E Flynn (Major Shareholder)
  2. Jonathan D Root (Director)

Who are the major institutional investors of Edgewise Therapeutics?

Edgewise Therapeutics' top institutional investors include:
  1. Orbimed Advisors LLC — 29.32%
  2. Novo Holdings A S — 11.75%
  3. Deerfield Management Company L.P. Series C — 8.27%
  4. Viking Global Investors LP — 7.05%
  5. RA Capital Management L.P. — 5.31%
  6. Citadel Advisors LLC — 5.01%

Which institutional investors are buying Edgewise Therapeutics stock?

In the previous quarter, EWTX stock was bought by institutional investors including:
  1. Orbimed Advisors LLC
  2. Novo Holdings A S
  3. Deerfield Management Company L.P. Series C
  4. Viking Global Investors LP
  5. RA Capital Management L.P.
  6. Citadel Advisors LLC
  7. Citadel Advisors LLC
  8. Cormorant Asset Management LP
Within the last year, these company insiders have bought Edgewise Therapeutics stock:
  1. James E Flynn (Major Shareholder)
  2. Jonathan D Root (Director)
Peter Thiel Bets Big On "Mushroom Boom."
LSD and "Mushroom stocks" are being listed on the NASDAQ and a recent breakthrough makes top investors VERY excited about the coming "Mushroom Boom."
Click Here To Read The Full Story